Search Results - Kirk E. Evoy

Editorial: Reviews in opioid use disorders by Wendy Walwyn, Kirk E. Evoy, Kirk E. Evoy

Connect to this object online.

Kratom as a potential substance use disorder harm reduction agent by MeShell Green, Nina Vadiei, Nina Vadiei, Charles A. Veltri, Oliver Grundmann, Oliver Grundmann, Kirk E. Evoy, Kirk E. Evoy

Connect to this object online.

Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern? by Alyssa M Peckham, Kirk E Evoy, Leslie Ochs, Jordan R Covvey

Connect to this object online.

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics by Kirk E Evoy, Chengwen Teng, Victor G Encarnacion, Brian Frescas, John Hakim, Stephen Saklad, Christopher R Frei

Connect to this object online.

Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States by Kirk E Evoy, Charles E Leonard, Jordan R Covvey, Leslie Ochs, Alyssa M Peckham, Samantha Soprano, Kelly R Reveles

Connect to this object online.

Quetiapine and olanzapine misuse prevalence in a US general population sample by Kirk E Evoy, PharmD, BCACP, BC-ADM, CTTS, Shelby Humpert, PharmD, Sorina Torrez, PharmD, Haneen Hussein, PharmD, Jordan R Covvey, PharmD, PhD, BCPS

Connect to this object online.

Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids by Payal H. Desai, PharmD, BCCCP, Olesya Taylor, PharmD, BCPS, Kunal J. Shah, PharmD, Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS, Alyssa M. Peckham, PharmD, BCPP

Connect to this object online.